High dose ifosfamide for patients with stage IV non small cell lung cancer: Phase II trial from the Groupe francais de pneumo-cancerologie (GFPC);Ifosfamide a forte dose chez des patients porteurs de cancers bronchiques non a petites cellules de stade IV: Essai de phase II du Groupe francais de pneumo-cancerologie (GFPC)

Bulletin du Cancer

Volumn 86, Issue 12, 1999, Pages 1017-1021

  Vergnenegre A ^a   Thomas, P ^a   Robinet, G ^a   Pibarot, M ^a   Paillotin, D ^a   Vernejoux, J M ^a   Thiberville, L ^a   Lena, H ^a   Kleisbauer, J P ^a   Gimonet, J F ^b  

^a Hopital du Cluzeau   (France)

^b NONE

Author keywords

Ifosfamide; Non small cell lung cancer

Indexed keywords

IFOSFAMIDE; MESNA; ALKYLATING AGENT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MESNA; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033369229     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. 1. Quoix E. Traitement des formes métastatiques. In: Milleron B, Depierre B, eds. Cancers broncho-pulmonaires. Paris: Arnette, 1998; 1 vol.: 335-42.
2. 2. Souquet PJ, Chauvin F, Boissel JP, Bernard JP. Meta-analysis of randomized trials of systematic chemotherapy versus supportive treatment in non resectable non-small cell lung cancer. Lung Cancer 1995; 12 : S147-S54.
3. 3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311 : 899-909.
4. 4. Marino P, Preatoni A, Cantoni A, Buccheri G. Single agent chemotherapy versus combination chemotherapy in advanced non small lung cancer: a quality and meta-analysis study. Lung Cancer 1995; 13 : 1-12.
5. 5. Brade WP, Herdrich K, Varini M. Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treatm Rev 1983; 10 : S175-S81.
6. 6. Brade WP, Herdrich K, Klein HO. Ifosfamide: dosing and scheduling. Contrib Oncol 1987; 26 : 22-52.
7. 7. Cervellino JC, Araujo CE, Pirisi C, Francia A, Cerruti R. Ifosfamide and mesna for the treatment of advanced squamous cell head an neck cancer. Oncology 1991; 48 : 89-92.
8. 8. Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD. Gynecologic oncology group experience with ifosfamide. Sem Oncol 1990; 7 : S6-S10.
9. 9. Pratt CB, Douglass EC, Etcubanas E, Goren MP, Wilimas JA. Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital 1983-1988. Sem Oncol 1989; 16 : S51-S5.
10. 10. Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard-and high dose schedules. Sem Oncol 1990; 17 : S68-S73.
11. 11. Davies SM, Pearson ADJ, Craft AW. Toxicity of high-dose ifosfamide in children. Cancer Chemother Pharmacol 1989; 24 : S8-S10.
12. 12. Brade WP, Herdrich K, Kachel-Fischer U, Araujo CE. Dosing and side-effects of ifosfamide plus mesna. J Cancer Res Clin Oncol 1991; 117 : S164-S86.
13. 13. Drings D. Ifosfamide in the treatment of bronchial carcinoma. Contr Oncol 1987; 26 : 294-318.
14. 14. Einhorn LH. Ifosfamide in small cell lung cancer. Sem Oncol 1989; 16: S19-S21.
15. 15. Elias AD, Eder JP, Schea T, Begg CB, Freill E, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol 1990; 8 : 170-8.
16. 16. Ettinger DS. Ifosfamide in the treatment of non-small cell lung cancer. Sem Oncol 1989; 16 : S22-S30.
17. 17. Hasuka MB, Bunn PA. Controversies in the nonsurgical treatment of stage III non-small cell lung cancer. Am Rev Desp Dis 1992; 145 : 967-77.
18. 18. Warenius HM, Hurman DC, Cottier B. High dose ifosfamide in small cell lung cancer. Br J Cancer 1986; 54 : 199-21.
19. 19. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 1990; 30 : 725-32.
20. 20. Lewis LD, Fitzgeral P, Mohan P, Thatcher N, Harper PG, Rogers HJ. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br J Clin Pharmac 1991; 34 : 77-82.
21. 21. Peake MD, Parker D. Ifosfamide as single-agent chemotherapy in inoperable non-small cell lung cancer. Lancet 1985; ii : 496-7.
22. 22. Thatcher N, Anderson H, Stout R, Carroll KB. Ifosfamide bolus therapy for advanced non-small cell lung cancer. Proceedings of the IVth-World congress on lung cancer. Toronto, Canada, 1985 : 201.
23. 23. Thatcher N, Smith DBS, Lind MJ, Anderson H, Barclay J, Phil MP, et al. Double alkylating agent therapy with ifosfamide and cyclophosphamide for advanced non small cell lung cancer. Cancer 1988; 61 : 14-8.
24. 24. Sheperd FA. Chimiothérapie du cancer bronchique non à petites cellules. In: Milleron B, Depierre B, eds. Cancers broncho-pulmonaires. Paris: Arnette, 1998; 1 vol. : 299-318.
25. 25. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin and versus navelbine alone in advanced non-small cell lung cancer: results of a european multicenter trial including 612 patients. J Clin Oncol 1994; 12 : 360-7.
26. 26. Bokemeyer C, Franzke A, Hartmann JT, Schöber C, Arseniev L, Metzner B, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80: 1221-7.
27. 27. Graziano SL, Herdon JE, Richards F, Difimo S, Modeas C, Duggan DB, et al. A phase 1 trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer: a cancer and leukemia group B study. Cancer 1993; 72 : 62-8.
28. 28. Chang AY, Asbury RF, Boros L, Garrow GC, Hsieh S. Ifosfamide-carboplatine-etoposide chemotherapy in patients with metastatic non-small cell lung cancer. Sem Oncology 1995; 22 : S9-S12.
29. 29. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporring results of cancer treatment. Cancer 1981; 47 : 207-14.
30. 30. World Health Organization. WHO recommended toxicity grading in WHO handbook for reporting results of cancer treatment. Organization WH, ed. Geneva, 1979.